Home            Past Issues            About IP            About IAP           Author Information            Subscription            Advertisement              Search  

   
correspondence

Indian Pediatr 2012;49: 996

Reply


  Vipin M Vashishtha

Convener, IAP Committee on Immunization, Mangla Hospital& Research Center, Shakti Chowk,
Bijnor, Uttar Pradesh, 246701,India
Email: [email protected]



It is not feasible to discuss all the issues related to all the available vaccines in a single meeting. Regarding your suggestion on use of reduced quantity of whole cell pertussis vaccines to adolescents and adults (through DTP/DT/Td), we cannot recommend this until adequate trials are conducted with proper protocol and after proper approval and clearance from national regulatory authority (NRA). Moreover, it is beyond the purview of IAPCOI to produce an indigenous affordable Tdap/pertussis vaccine for the adolescents.

IAPCOI has recommended two dose schedule for prevention of ‘breakthrough varicella’ [1]. Following are the rationale behind IAPCOI’s recommendations:

1. The recommended ages for routine first (at age 12-15 months) and second (at age 4-6 years) doses of varicella vaccine are harmonized with the recommendations for MMR vaccine use and intended to limit the period when children have no varicella antibody. The recommended age for the second dose is supported by the current epidemiology of varicella, with low incidence and few outbreaks among preschool-aged children and higher incidence and more outbreaks among elementary school-aged children.

2. Although, most studies are done when 2nd dose is given after 3 months of the first, there are few trials where the two schedules were compared and it was concluded that among children, VZV antibody levels and GMTs after 2 doses administered 4-6 years apart were comparable to those obtained when the 2 doses were administered 3 months apart (seroconversion: 99.2% vs 99.6%, GMTs: 212.4 vs 142.6, respectively).

3. However, the CMI responses measured by mean stimulation index (SI), a marker of cell-mediated immunity were 36.9 for 2nd dose after 3 months of primary dose, and 58.6 when 2nd dose was given at 4-6 yrs of age [2].

References 

1. IAP Guidebook on Immunization, 2009-11. Eds. Yewale V, Choudhury P, Thacker N. Individual vaccines; Varicella vaccine. Available from: http://www.iapcoi. com/hp/pdf/IAP%20GUIDE%20BOOK%20ON%20 IMMUNIZATION%20INDIVIDUAL%20VACCINES.pdf. Accessed on September 4, 2012.

2. MMWR, Recommendations and Reports. Prevention of Varicella. Recommendations of the Advisory Committee on Immunization Practices (ACIP). June 22, 2007/ 56(RR04);1-40. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm.

 

Copyright 1999-2012 Indian Pediatrics